ProfileGDS5678 / 1430074_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 71% 69% 68% 67% 68% 72% 71% 71% 68% 68% 69% 70% 69% 70% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.4693971
GSM967853U87-EV human glioblastoma xenograft - Control 24.2232669
GSM967854U87-EV human glioblastoma xenograft - Control 34.1939868
GSM967855U87-EV human glioblastoma xenograft - Control 44.0905267
GSM967856U87-EV human glioblastoma xenograft - Control 54.114168
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.4816372
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.4963971
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.4175871
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.1345968
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.1199168
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.2221869
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.3513770
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.2580969
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.3173770